Precigen (PGEN) Stock Forecast: StockMap's 2-Week Call
PGEN stock forecast: StockMap's model makes no two-week call on Precigen after the Nov 18 close: its evidence is split, 8 reasons for and 7 against. Right in 0 of 3 two-week windows on PGEN since Oct 8; by chance, a call on the same dates was right 61% of the time.
Precigen last closed at $4.27, -0.47% on the session.
Against the IVW growth benchmark the position is -0.49% over the forecast window.
Precigen's market cap is $1.53B as of November 18, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -1 (too close to call).
Where PGEN sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 8 bullish and 7 bearish.
Agreement across those insights is 47%.
13 daily calls for PGEN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Precigen in the 4th percentile on valuation and the 93rd percentile on return on equity, where 100 is best.
Precigen is classified under Health Care / Biotechnology.
StockMap tracks Precigen as the 103rd largest of the 393 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 195 Moderate Underperform, 141 Neutral, 42 Strong Underperform and 15 Moderate Outperform.
On that composite Precigen ranks 71st of 393 in the group, against a group median of -0.27.